Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.81 |
| ▸ | HPGD | P15428 | 3/20 | 0.81 |
| ▸ | GLA | P06280 | 2/20 | 0.81 |
| ▸ | GAA | P10253 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL300825 | 0.93 | KDM4E (0.82) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL300924 | 0.91 | KDM4E (0.80) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL291560 | 0.90 | KDM4E (0.81) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL19254092 | 0.90 | KDM4E (0.81) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL297362 | 0.90 | KDM4E (0.72) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL301283 | 0.89 | KDM4E (0.81) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL297560 | 0.88 | KDM4E (0.86) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL301183 | 0.88 | KDM4E (0.86) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1750414 | 0.87 | KDM4E (0.79) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL300856 | 0.87 | KDM4E (0.76) | KDM4EALDH1A1HPGDGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | claimed |
| CN-107976546-B | Inhibition of phosphorylation of TOR kinase inhibitory Activity markers PRAS40, GSK 3-beta, or P70S6K1 | 西格诺药品有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-110721186-A | Treatment of prostate cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-107157990-B | Treatment of cancer with TOR kinase inhibitors | 西格诺药品有限公司 | 2020-01-07 | — | — | CN | disclosed |
| US-9555033-B2 | Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9493466-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140113904-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130245026-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245027-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245029-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245028-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130102613-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-8383634-B2 | Methods of treatment using heteroaryl compounds and compositions thereof | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-20 | — | — | US | disclosed |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2011-09-15 | — | — | US | disclosed |
| US-7968556-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2078018-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245027-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, BRCA1 | KDM4E 1384/4885ALDH1A1 4555/4885HPGD 2421/4885 |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | STK11, STK16, STK10 | KDM4E 3306/4885ALDH1A1 3059/4885HPGD 1293/4885 |
| US-20130245026-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, CHEK2, CHEK1 | KDM4E 2384/4885ALDH1A1 4280/4885HPGD 1942/4885 |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | JAK2, CHEK2, PHKG1 | KDM4E 1690/4885ALDH1A1 2430/4885HPGD 1819/4885 |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | STK16, STK10, STK11 | KDM4E 2984/4885ALDH1A1 3436/4885HPGD 936/4885 |
| US-20130102613-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | KDM4E 877/4885ALDH1A1 4675/4885HPGD 2833/4885 |
| US-20130245029-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | EWSR1, ELF3, MTOR | KDM4E 851/4885ALDH1A1 3832/4885HPGD 3763/4885 |
| US-20130245028-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | ELF3, ERG, MTOR | KDM4E 664/4885ALDH1A1 4026/4885HPGD 3172/4885 |
| US-20140113904-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, TNNI3K | KDM4E 1874/4885ALDH1A1 4005/4885HPGD 1595/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | KDM4E 2069/4885ALDH1A1 2113/4885HPGD 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.